Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284322 · ClinicalTrials.gov registry record · Phase 1
Fresolimumab In Systemic Sclerosis
A Phase 1 study of Diffuse Systemic Sclerosis, sponsored by Boston University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01284322: Completed Phase 1 study of Diffuse Systemic Sclerosis, sponsored by Boston University.
NCT01284322 is a Phase 1 study of Diffuse Systemic Sclerosis that has completed, run by Boston University. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01284322, a Phase 1 study of Diffuse Systemic Sclerosis, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
Conditions Studied
Interventions
- DRUG Fresolimumab
Study Locations (1)
Massachusetts
- Boston University School of Medicine; Rheumatology/Arthritis Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT01284322 record still lists
NCT01284322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Diffuse Systemic Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Fresolimumab is the first listed.
NCT01284322 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01284322 about?
NCT01284322 is a clinical study titled "Fresolimumab In Systemic Sclerosis". The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
What is the current status of trial NCT01284322?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-01. Estimated completion is 2014-03.
What conditions does trial NCT01284322 study?
This clinical trial studies the following conditions: Diffuse Systemic Sclerosis.
What interventions are being tested in trial NCT01284322?
The interventions under investigation include: Fresolimumab (DRUG).
Who is sponsoring clinical trial NCT01284322?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01284322 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01284322's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia